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Case report Burkitt's lymphoma mimicking EBV disease as first 
sign of vertical HIV infection in an adolescent
Veronica Santilli*1, Nadia Mora1, Angela Aquilani1, Hyppolite K Tchidjou1, Giuseppe Pontrelli1, Rita De Vito2, 
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Abstract
Burkitt's Lymphoma (BL) rarely represents the first clinical manifestation of vertical HIV infection in adolescent in 
Western Europe. We report the case of a 17 year-old boy with two week history of fever and enlarged cervical lymph 
nodes firstly misdiagnosed as EBV infection, subsequently diagnosed as Burkitt's Lymphoma and vertical HIV infection.
Background
Human immunodeficiency virus (HIV)-infected children
are at increased risk of developing cancer, particularly in
the later stages of acquired immune deficiency syndrome
(AIDS) [1]. The introduction of efficacious regimens of
antiretroviral treatment has resulted in a substantial and
dramatic decrease in AIDS-related opportunistic infec-
tions and cancers [1]. However, despite this progress,
recent data show as HIV infection itself represents a
major risk factor for developing cancers and non-Hodg-
kin's Lymphoma (NHL) which remains the most frequent
malignancy in subjects with AIDS [2].
Case Report
A 17 years-old boy was admitted with a short history of
fever, tonsillitis and monolateral enlarged cervical lymph
nodes non responsive to antibiotic therapy with
Clarithromycin. Familiar history showed mother's death
for lymphoma and remote history was silent with normal
growth and neurocognitive development and a single epi-
sode of bronchopneumonia at the age of 4 years. Initial
clinical examination revealed good general condition
except for the enlargement of right side cervical lymph
node 3 cm in diameter hard and painful, hepatosplenom-
egaly, pharyngeal hyperemia. No other alterations were
found, even through neurological examination. Biological
tests disclosed the following values: haemoglobin 11.9 g/
dl; leucocytes 5.78 × 10^3/uL with 39,5% lymphocytes
and 50,7% neutrophils; platelets 91 × 10^3/uL; sedimen-
tation rate, 77 mm/h; CRP 1.36 mg/dl; LDH 523 UI/L;
GOT 57 UI/L; GPT 41 UI/L [Table 1].
On the basis of clinical and laboratory signs we per-
formed microbiological tests to rule out Epstein-Barr
virus (EBV) infection, our first diagnostic suspect. Serol-
ogy test for EBV showed the presence of anti-EBNA and
VCA IgG whereas IgM anti-VCA resulted negative. In
parallel, polymerase chain reaction (PCR) detected the
presence of 20.000 EBV blood copies/ml. ELISA test for
hepatitis A (HAV), hepatitis C (HCV), hepatitis B (HBV),
cytomegalovirus (CMV) resulted IgM and IgG negative.
Cervical ultrasound showed enlarged right side cervical
lymph nodes 4,5 cm in diameter with a loss of hilar echo-
genic central and hilar architecture, presence of intran-
odal necrosis, calcification and high peripheral and
central perfusion. There were also multiple nodes in the
left side of about 1 cm in diameter. Abdominal ultrasound
showed hepatosplenomegaly and modest increase of
hepatic hilus and retroperitoneal lymph nodes. Mycobac-
terial infection was excluded by Interferon gamma release
assay.
Due to the persistence of tonsillopharyngitis and lym-
phoadenopathy over two weeks of follow-up, the patient
underwent open biopsy showing a malignant population
of round monomorphic B cells, interspersed with mac-
rophages forming the "stars" in the "starry sky" histology
pattern typical of the Burkitt's Lymphoma (BL) [Fig 1].
The malignant cells were strongly positive for CD20,
CD79a and CD10 [Fig 2, 3] and T-lymphocyte markers
(CD3 and TdT) were negative. Detection of EBV RNA in
corresponding tumor tissues was carried out using in situ
hybridization. In view of the hypergammaglobulinemia
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(IgA 608 mg/dl, IgG 2306 mg/dl and IgM 440 mg/dl)
associated with severe immunodeficiency (CD4 count
114/mm3-5%) HIV infection was suspected and con-
firmed by standard ELISA serology test and quantitative
PCR (HIV viral load 118.000 copies/ml). Thus, diagnosis
of HIV-related BL was established and subsequently con-
firmed in his mother by the acquisition of her medical
history. To investigate tumour staging Total Body CT
scan was performed confirming the presence of enlarged
cervical and abdominal lymph nodes with typical pat-
terns of malignancy. Bone scintigraphy and bone marrow
biopsy were negative. Brain MRI, lumbar puncture and
cerebrospinal fluid cytology showed any involvement of
central nervous system (CNS). However due to the pres-
ence of third branch trigeminal nerve palsy CNS involve-
ment was considered. Staging classification was Ann
Arbor Stage IV.
Table 1: Patient's haematological data on admission and during follow-up.
On admission After 5 months 
of 
Chemotherapy 
and HAART
After 10 months 
of follow up
After 2 years of 
follow up
After 3 years of 
follow up
Hb (g/dl) 11.9 11.6 14.6 15.5 16.1
RBC (×10^6/uI) 4.38 3.87 4.57 4.91 5.07
WBC (×10^3/uI) 5.78 5.21 6.82 8.36 8.25
Neu (×10^3/uI) 2.93 2.63 3.41 5.01 5.10
Lym (×10^3/uI) 2.20 1.94 2.82 2.51 2.46
PLT (×10^3/uI) 91 177 230 221 218
CRP mg/dl 1.36 0.25 0.20 < 0.05 0.47
LDH (UI/L) 523 441 354 248 286
GOT (UI/L) 57 16 22 18 18
GPT (UI/L) 41 13 12 12 12
IgA (mg/dl) 608 288 284 320 339
IgG (mg/dl) 2306 707 1256 1025 933
IgM (mg/dl) 440 122 250 145 134
HIV Viral Load
(copies/ml)
118.000 320 <50 <50 <50
CD4+%/abs
(cell/uI)
5%/114 9%/174 11%/298 21%/527 25%/603
EBV RNA blood/
plasma
(copies/ml)
0/20.000 0/43.000 113.000/5.400 0/0 0/0Santilli et al. Italian Journal of Pediatrics 2010, 36:34
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The patient was treated according to the Italian Associ-
ation of Pediatric Hematology Oncology (AIEOP) proto-
col which includes dexamethasone, ifosfamide,
methotrexate, cytarabine, etoposide phosphate, vincris-
tine, cyclophosphamide, daunomycin and intrathecal
administration of prednisolone, cytarabine and metho-
trexate. He received four courses of chemotherapy result-
ing in a rapid tumor regression followed by the complete
remission (CR) after the fourth course. The neutropenic
period lasted from day 7 to day 12 after treatment with-
out further chemotherapic toxicity. During this period he
received antibacterial, antiviral and antifungal prophy-
laxis as well as blood transfusions and G-CSF support. In
parallel with chemotherapy, highly active antiretroviral
therapy (HAART) based on four drugs (lopinavir/ritona-
vir + abacavir/lamivudina) was started.
The patient, over the last 3 years, has been regularly fol-
lowed-up by the HIV Unit of our Hospital. Blood count,
LDH, EBV, HIV viral load and CD4 cell counts were
detected every 3 months. Abdominal and cervical ultra-
sound were performed at regular intervals of six months.
Viral load resulted undetectable (number of copies <50/
ml) after 10 months of HAART initiation. The patient
remains in good health condition maintaining CR over
the last 3 years of follow-up. HIV plasma viral load is still
undetectable with good immune reconstitution (CD4
count 603/mm3 or 24,5%) [Table 1].
Discussion
We report a case of vertical HIV infection presenting
with atypical features because of the timing of presenta-
tion and the long term period free of the characteristic
early signs and symptoms of AIDS.
Human immunodeficiency virus (HIV)-infected chil-
dren have an increased risk of developing cancer, particu-
larly in the later stages of acquired immune deficiency
syndrome (AIDS) and AIDS-related non-Hodgkin's lym-
phomas are one of the most common AIDS-defining
malignancies [1].
This seems to be related to multiple factors, including
the transforming properties of the human retrovirus
itself, the duration and degree of immunodeficiency and
viral exposure [2], the immune activation leading to B cell
proliferation and further infections with other lymph
tropic viruses such EBV [3,4].
Without Antiretroviral Treatment (ART), progression
of HIV infection in vertically infected children is most
rapid than in adults and about one-fifth progress to seri-
ous clinical illness or die before one year of age [5]. In
fact, in HIV-1- infected non treated children the rates of
progression to AIDS are 17% at 1 year of age and 35% at 5
Figure 1 Hematoxylin and eosin stainig: Hematoxylin and eosin 
section showing monomorphic population of neoplastic lym-
phoid cells and large pale macrophages forming the "stars" in the 
"starry sky" typical of Burkitt Lymphoma (HE 20×).
Figure 2 Immunohistochemical staining: Immunohistochemistry 
showing tumor cells are positive for CD20 (CD20 20×).
Figure 3 Immunohistochemical staining: Immunohistochemistry 
showing tumor cells are positive for CD10 (CD10 20×).Santilli et al. Italian Journal of Pediatrics 2010, 36:34
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years of age [6-8]. For this reason, BL is a common co-
morbidity of HIV infection particularly in developing
countries, where people do not have access to antiretrovi-
ral drugs [9], but rarely represents the initial clinical man-
ifestation of vertical HIV infection in adolescent in
Western Europe. Indeed, the introduction of protocols to
prevent mother-to-child transmission and efficacious
regimens of early antiretroviral treatment have resulted
in a substantial and dramatic decrease in AIDS-related
opportunistic infections and cancers in both adults and
children [1,4,10-12].
However, despite this progress, recent data show as
HIV infection itself represents a major risk factor for
developing cancers [13] especially in young adults, a new
phenomena made possible by the improved survival fol-
lowed by HAART use and the low adherence to treat-
ment reported during this age [14]. Within HIV-related
tumors, Non Hodgkin's Lymphomas remain the most fre-
quent malignancies of children with AIDS [15,16]. In the
developed countries NHL accounts for 65%-83% of
AIDS-related malignancies, and BL rates about 40% of
HIV-related NHL in children [17,18]. Hence, BL rarely
represents the first sign of HIV infection in childhood
whose HIV exposure status is not known [19]. Interest-
ingly in this case, although the patient vertically acquired
HIV infection, he had an asymptomatic neonatal period
and childhood, with normal growth and development, up
to 16 years old. As previously discussed this silent patho-
logical history led to misdiagnose the vertical HIV infec-
tion. However, the presence of marked
hypergammaglobulinemia associated with severe immu-
nodeficiency and the diagnosis of BL allowed us to sus-
pect and subsequently diagnose HIV infection and start
an adequate treatment.
Before the widespread use of HAART, in patients with
BL and HIV, the chemotherapy was less aggressive than
in non-HIV-infected patients, with parallel correspond-
ing poorer results. This approach is presently abandoned,
since recent cumulative evidences have showed compara-
ble results with full intensive chemotherapy between HIV
infected and non-infected individuals in terms of toxicity
effects and survival [20]. Indeed, although the patient
hereby described received high-dose polychemotherapy,
no serious toxic effects neither life-threatening infections
were recorded.
Patients who developed NHL but who did not undergo
HAART had better survival, particularly when compared
with patients who developed NHL after HAART initia-
tion [21-23]. Thus, starting antiretroviral therapy in addi-
tion to chemotherapy after the diagnosis of NHL may
represent an effective salvage therapy even for those
patients who have NHL as their AIDS-defining event, as
in this case [22,23].
Conclusion
This case illustrates a HIV-associated BL, initially misdi-
agnosed as a common mononucleosis syndrome. It repre-
sents an atypical presentation of vertical HIV infection
because of the total absence of characteristic early signs
and symptoms of AIDS.
This case highlights the increased risk to develop NHL
of young HIV positive individuals. Indeed, despite the
introduction of antiretroviral therapy several studies
report a lesser decrease in incidence rates of NHL com-
pared with others type of cancers (i.e. Kaposi's sarcoma)
in this population [13,24]. Recent data show as immuno-
deficiency and HIV viremia are major risk factors for
developing cancers [2,13,24] especially in young adults.
In this optic, lower adherence to treatment reported dur-
ing this age [14] might represent an emerging problem.
Thus, access to NLH screening programmes should be
regularly offered to all HIV-positive adolescents and
young adults [24].
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